SCHEMBL19968902

SCHEMBL19968902

COc1ccc(Cl)cc1-c1nc(NS(=O)(=O)c2cccc(N3CCC[C@H](C)C3)n2)ccc1C(F)(F)F

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
GALR2 O43603 1/20 0.38
GALR1 P47211 1/20 0.38
ALDH1A1 P00352 3/20 0.36
MAPT P10636 2/20 0.36
LMNA P02545 1/20 0.36
POLB P06746 1/20 0.36
MAPK1 P28482 1/20 0.36
HTR6 P50406 1/20 0.36
LRRK2 Q5S007 1/20 0.36
RBP4 P02753 4/20 0.35
TP53 P04637 1/20 0.35
AXL P30530 1/20 0.34
UTS2R Q9UKP6 2/20 0.34
ALPL P05186 2/20 0.34
SCN9A Q15858 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
CNR1 P21554 1/20 0.34
SCN1A P35498 2/20 0.34
SCN8A Q9UQD0 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19968894 1.00 GALR2 (0.38) GALR2GALR1ALDH1A1MAPTLMNA
SCHEMBL19968895 0.92 HMOX1 (0.37) GALR2GALR1ALDH1A1MAPTLMNA
SCHEMBL19968892 0.91 TP53 (0.38) MAPTHTR6RBP4TP53SCN9A
SCHEMBL23770670 0.87 GALR2 (0.36) GALR2GALR1ALDH1A1MAPTLMNA
SCHEMBL19968888 0.87 GALR2 (0.36) GALR2GALR1ALDH1A1MAPTLMNA
SCHEMBL19968885 0.85 HSD11B1 (0.40) ALDH1A1MAPTLMNAPOLBMAPK1
SCHEMBL19927799 0.83 RBP4 (0.36) HTR6RBP4TP53SCN9ACNR1
SCHEMBL19951333 0.83 RBP4 (0.36) HTR6RBP4TP53SCN9ACNR1
SCHEMBL19968890 0.83 HMOX1 (0.37) ALDH1A1MAPTLMNAMAPK1RBP4
SCHEMBL19951381 0.83 RBP4 (0.36) ALDH1A1MAPTHTR6RBP4TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180072673-A1 N-(pyridin-2-yl)pyridine-sulfonamide Derivatives and their Use in the Treatment of Disease NOVARTIS AG (CH) 2018-03-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180072673-A1 N-(pyridin-2-yl)pyridine-sulfonamide Derivatives and their Use in the Treatment of Disease CFTR, P2RY1, P2RX5 GALR2 2904/4885GALR1 3207/4885ALDH1A1 1455/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.